ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR/ARHP Annual Meeting 2018

Abstract Number: 1871

A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE

Maureen A. McMahon1, Jennifer M. Grossman2, Lori Sahakian3, Christina Charles-Schoeman4, John Fitzgerald1, Mihaela Taylor4, Alan Gorn1, Eloise Olmos1, Daniel J. Wallace5, Bevra H Hahn1,4 and Brian Skaggs4, 1Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 2Div of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 3UCLA David Geffen School of Medicine, Los Angeles, CA, 4Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, 5Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR/ARHP Annual Meeting 2018

Keywords: atherosclerosis and biomarkers, Lupus

Session Information

Date: Monday, October 22, 2018

Title: 4M081 ACR Abstract: Edmond L. Dubois, MD Memorial Lecture: SLE–Clinical (1870–1874)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: There is a well-documented increase in atherosclerosis (ATH) in SLE that is not fully explained by traditional risk factors. Several non-Framingham biomarkers, including pro-inflammatory HDL (piHDL), leptin, plasma soluble TNF-like weak inducer of apoptosis (sTWEAK), and homocysteine are individually associated with subclinical ATH in SLE. We previously demonstrated that these biomarkers, combined with clinical variables such as age and diabetes, create a risk profile we have called PREDICTS. The PREDICTS profile more accurately identified SLE patients at risk for future subclinical ATH progression than any one variable alone. We set out to determine whether a high-risk PREDICTS score could also identify patients at risk for future cardiovascular events.

Methods: 392 SLE patients participated in this longitudinal prospective cohort study. 205 patients were included in this analysis, based on availability of 10-year cardiac event and/or mortality data. piHDL was measured using a published cell-free assay. Leptin and sTWEAK were determined at baseline using ELISA (R&D Biosystems). Homocysteine was determined by radioimmunoassay in the clinical laboratory of an academic medical center. Cardiac events were defined as myocardial infarction, a positive stress test, angioplasty, or percutaneous coronary intervention. Cerebrovascular events were defined as stroke or documented TIA. We defined high-risk PREDICTS as ≥ 3 of identified predictors or diabetes + ≥ 1 predictor.

Results: 16.1% (33) of SLE patients experienced a cerebrovascular accident during the 10-year follow-up period. 8.3% (17) of subjects had a cardiac event. 8.3% (17) of subjects died. Patients with a high-risk PREDICTS score at cohort entry were significantly more likely to have a cerebrovascular event (19.1% vs. 7.0%, p=0.04), or a cardiac event (10.9% vs. 0%, p=0.012). In addition, a high-risk baseline PREDICTS score also was also more likely to be found in patients that suffered any cardiovascular event or death (34.4% vs. 7%, p<0.0001). In multivariate analysis, baseline high-risk PREDICTS associated with a 3.7-fold increased odds for death or cardiovascular event over 10 years (p=0.004). Hypertension at baseline also was associated with increased odds for death or cardiovascular event (OR=4.9, p=0.001). No association with death or cardiovascular events were observed with hyperlipidemia, baseline carotid plaque, gender, or tobacco use.

Conclusion: A high-risk PREDICTS score and a history of hypertension at cohort entry confer significantly increased odds for a cardiovascular event or death in SLE patients over a 10-year follow-up. Further studies are necessary to identify proactive treatment strategies to prevent cardiovascular morbidity and mortality in SLE.


Disclosure: M. A. McMahon, None; J. M. Grossman, None; L. Sahakian, None; C. Charles-Schoeman, Bristol Myers Squibb, AbbVie, Octapharma, and Pfizer, 2,Regeneron-Sanofi, Pfizer, Octapharma, Amgen, and Gilead, 5; J. Fitzgerald, None; M. Taylor, Celgene Corporation, 8,AbbVie Inc., 8; A. Gorn, None; E. Olmos, None; D. J. Wallace, Program Advisor to Lupus Foundation of America, 5; B. H. Hahn, Janssen Research & Development, LLC, 2; B. Skaggs, None.

To cite this abstract in AMA style:

McMahon MA, Grossman JM, Sahakian L, Charles-Schoeman C, Fitzgerald J, Taylor M, Gorn A, Olmos E, Wallace DJ, Hahn BH, Skaggs B. A High Cardiovascular Biomarker Panel Risk Score Is Associated with Increased 10-Year Risk of Cardiovascular Events and Death in SLE [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/a-high-cardiovascular-biomarker-panel-risk-score-is-associated-with-increased-10-year-risk-of-cardiovascular-events-and-death-in-sle/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-high-cardiovascular-biomarker-panel-risk-score-is-associated-with-increased-10-year-risk-of-cardiovascular-events-and-death-in-sle/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology